Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Influenza: early-phase trial registry
27 of 157 indexed Influenza trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #70 of 28,707 conditions by registered trial count.
157 US clinical trials · 27 currently recruiting · #70 of 28,707 conditions by registered trial count
Influenza: 157 US clinical trials tracked, 27 recruiting.
Influenza is the subject of 157 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 73 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 36 of these trials.
Enrollment posture brief
Registry condition influenza
OPEN 27 | RECR 17% | LATE 42 | EARLY 73 | RANK #70 | SPON 36
Volume-matched condition peers
Nearest open-share peer: Arthritis, Rheumatoid (17% recruiting · 29 trials)
Influenza lists 27 open slots (17% of 157 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Influenza on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Influenza is recruiting below its size-band peers.
27 of 157 indexed trials (17.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Influenza research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 36 of 157 trials (22.9%). 62 distinct sponsors appear on at least one study for this condition label.
-
Typical Influenza enrolment sits around 219 participants.
Median target enrolment is 219 among the 157 trials that report a genuine target (sentinel values excluded). 55 of those (35%) plan for fewer than 100 participants.
-
Influenza research is mostly interventional.
134 interventional and 23 observational studies make up this index (85.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
157 total, page 2 of 4
Study of Quadrivalent Influenza Vaccine Among Children
Sanofi Pasteur, a Sanofi Company
NCT01240746
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
GlaxoSmithKline
NCT00979602
Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts
Columbia University
NCT02284594
REDucing Influenza Among University Students, University of California at Berkeley
Centers for Disease Control and Prevention
NCT00448773
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
BioNTech SE
NCT06821061
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
Protein Sciences Corporation
NCT01825200
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
ModernaTX
NCT05827926
A Study of Exclusion Criteria in a University Population
University of Michigan
NCT01472536
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
Novartis Vaccines
NCT00972816
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
Protein Sciences Corporation
NCT02290509
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
GlaxoSmithKline
NCT00985088
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
Sanofi Pasteur, a Sanofi Company
NCT06641180
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01227967
Sanofi H1N1 + TIV - Adults and Elderly
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00943878
Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults
GlaxoSmithKline
NCT00985673
Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
Protein Sciences Corporation
NCT00539864
A Study of Influenza Virus Vaccines in Children and Adults
Sanofi Pasteur, a Sanofi Company
NCT00988143
H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00294099
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
Sanofi Pasteur, a Sanofi Company
NCT05608005
Sanofi Pasteur, TIV + H1N1, Pediatric Population
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00943202
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza
MDVI
NCT01068912
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
Sanofi
NCT00391391
H5N1 (Clade 2) Vaccination of Adults and Elderly
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00680069
Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry
GlaxoSmithKline
NCT02148211
Xofluza-Wearables Feasibility-Study
Children's Hospital of Philadelphia
NCT06161454
CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00943488
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
Hoffmann-La Roche
NCT03684044
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
Alachua Government Services
NCT01320696
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
MedImmune
NCT00192140
Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00311727
H5 Booster After a Two Dose Schedule
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00240968
Audio Data Collection for Identification and Classification of Coughing
HealthMode
NCT04326309
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
MedImmune
NCT00946101
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
GlaxoSmithKline
NCT01974895
Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness
Emergo Therapeutics
NCT04610047
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
MedImmune
NCT02743117
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
MedImmune
NCT02473510
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
MedImmune
NCT03158038
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
MedImmune
NCT00125944
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
Sanofi Pasteur, a Sanofi Company
NCT01430819
H5N1 Mix and Match With MF59
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01317745
Comparison of Flu Vaccine Doses in Children
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01164553
Gene Signatures of Influenza Vaccine Responses in Older Adults
Mayo Clinic
NCT03603509
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Sanofi Pasteur, a Sanofi Company
NCT03308825
Influenza Vaccine Randomized Educational Trial: Adult
Columbia University
NCT02907645
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
Protein Sciences Corporation
NCT01959945
Immunogenicity and Safety of Different Doses of Fluzone® Influenza
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00253734
Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults
Sanofi Pasteur, a Sanofi Company
NCT02563093
Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
National Heart, Lung, and Blood Institute (NHLBI)
NCT01191853
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
GlaxoSmithKline
NCT00693706
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 42 |
| Phase 2 | 31 |
| Phase 3 | 17 |
| Phase 4 | 25 |
Top Sponsors
Named interventions
Most-linked intervention names on Influenza records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Influenza trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Influenza page
157 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Influenza trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Influenza trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Influenza condition card totals 157 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.